ADVANZ PHARMA Corp. Announces First Quarter 2019 Results

Friday, May 10, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Three months ended

(in $000's)

Mar 31, 2019

Mar 31, 2018

Net income (loss) for the period

(7,988)

(55,694)

Interest and accretion expense

26,739

80,122

Interest income

(535)

(706)

Income taxes

66

4,704

Depreciation

805

470

Amortization of intangible assets

53,097

65,607

EBITDA

72,184

94,503

Restructuring related, acquisition and other

4,471

15,494

Share-based compensation expense

1,223

1,267

Fair value loss on purchase consideration and derivatives

425

Foreign exchange (gain) loss

(526)

1,341

Unrealized foreign exchange (gain) loss

(12,262)

(41,006)

Adjusted EBITDA

65,090

72,024



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store